Ensysce Biosciences Inc (ENSC)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 12-2019 | 12-2018 | 12-2017 | 12-2006 | 12-2005 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 1,061 | 1,658 | 2,090 | N/A | N/A |
| Receivables | N/A | 171 | N/A | N/A | N/A |
| TOTAL | $1,200 | $1,916 | $2,307 | $N/A | $N/A |
| Non-Current Assets | |||||
| Other Non-Current Assets | 195,312 | 202,916 | 200,119 | 0 | 0 |
| TOTAL | $195,312 | $202,916 | $200,119 | $N/A | $N/A |
| Total Assets | $196,512 | $204,832 | $202,426 | $N/A | $N/A |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 2,771 | 429 | 112 | 0 | 0 |
| Other current liabilities | N/A | 9 | 41 | N/A | N/A |
| TOTAL | $2,771 | $438 | $156 | $N/A | $N/A |
| Non-Current Liabilities | |||||
| Long Term Debt | 566 | N/A | N/A | N/A | N/A |
| Other Non-Current Liabilities | 188,175 | 199,392 | 197,270 | 0 | 0 |
| TOTAL | $188,741 | $199,394 | $197,270 | $N/A | $N/A |
| Total Liabilities | $191,512 | $199,832 | $197,426 | $N/A | $N/A |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 7 | 7 | 7 | N/A | N/A |
| Common Shares | 1 | 1 | 1 | N/A | N/A |
| Retained earnings | -137 | 2,091 | -31 | N/A | N/A |
| TOTAL | $5,000 | $5,000 | $5,000 | $N/A | $N/A |
| Total Liabilities And Equity | $196,512 | $204,832 | $202,426 | $0 | $0 |